null

SMILES CCc1cc(F)c2nc(N3CCC(CC3)N[C@@H]3CCOC3)c(-c3nc(C)no3)c(C)c2c1

InChI Key InChIKey=QPZPCDQETGMDJR-GOSISDBHSA-N

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 5 hits for monomerid = 50531916   

TargetKappa-type opioid receptor(Homo sapiens (Human))
BLACKTHORN THERAPEUTICS, INC.; THE SCRIPPS RESEARCH INSTITUTE

US Patent
LigandPNGBDBM50531916(CHEMBL4456582 | US10676469, Compound 145 | US11124...)copy SMILEScopy InChI
Affinity DataIC50: 1nMAssay Description:The cell line for the OPRK1 antagonist assay stably expresses the following elements: The carboxy terminus of the OPRK1 receptor has a 7-amino acid l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q26W9F41US Patent
TargetMu-type opioid receptor(Homo sapiens (Human))
BLACKTHORN THERAPEUTICS, INC.; THE SCRIPPS RESEARCH INSTITUTE

US Patent
LigandPNGBDBM50531916(CHEMBL4456582 | US10676469, Compound 145 | US11124...)copy SMILEScopy InChI
Affinity DataIC50: 1.00E+3nMAssay Description:The purpose of this assay is to confirm the potency and selectivity of compounds synthesized to be OPRK1 Antagonists. This assay monitors the OPRMu1 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q26W9F41US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
BLACKTHORN THERAPEUTICS, INC.; THE SCRIPPS RESEARCH INSTITUTE

US Patent
LigandPNGBDBM50531916(CHEMBL4456582 | US10676469, Compound 145 | US11124...)copy SMILEScopy InChI
Affinity DataIC50: 0.780nMAssay Description:Antagonist activity at GAL4-VP16-fused KOR (unknown origin) expressed in human U2OS cells co-expressing Tango-OPRK1-BLA assessed as inhibition of U-5...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2CV4N6QPubMed
TargetDelta-type opioid receptor(Homo sapiens (Human))
The Scripps Research Institute

Curated by ChEMBL
LigandPNGBDBM50531916(CHEMBL4456582 | US10676469, Compound 145 | US11124...)copy SMILEScopy InChI
Affinity DataIC50: 1.00E+4nMAssay Description:Antagonist activity at GAL4-VP16-fused DOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migra...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2CV4N6QPubMed
TargetMu-type opioid receptor(Homo sapiens (Human))
BLACKTHORN THERAPEUTICS, INC.; THE SCRIPPS RESEARCH INSTITUTE

US Patent
LigandPNGBDBM50531916(CHEMBL4456582 | US10676469, Compound 145 | US11124...)copy SMILEScopy InChI
Affinity DataIC50: 1.10E+3nMAssay Description:Antagonist activity at GAL4-VP16-fused MOR (unknown origin) expressed in human U2OS cells assessed as inhibition of DAMGO-induced beta-arrestin migra...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails Article
BindingDB Entry DOI: 10.7270/Q2CV4N6QPubMed